Foundayo Hits Phase 3 Sleep Apnea Goal; Lilly Eyes FDA Filing by End-2026
LLY sits 66% above its 52-week low of $850.51.
Summary
Lilly's oral GLP-1 Foundayo met the primary endpoint in a Phase 3 sleep apnea trial, with patients losing about 11% of body weight after 52 weeks. Lilly plans to file for U.S. approval by end-2026, adding a new indication to a drug already backed by the ACHIEVE-4 cardiovascular data reported in late September. Separately, Lilly and Hims & Hers will sell Zepbound and Foundayo to eligible patients at self-pay prices starting at $299 and $149 a month, with Hims agreeing not to sell compounded copies — a direct cash-pay channel that sidesteps insurer coverage friction. Jefferies kept its Buy rating and lifted its target to $1,700 from $1,610, citing overseas GLP-1 demand; the stock rose 3.4% to $1,400.04 Monday and sits near its 52-week high. The sleep apnea filing timeline is the concrete milestone to track.
At the time of this announcement, LLY was trading at $1,411.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3T. The 52-week trading range was $850.51 to $1,453.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.